Nitric oxide stimulates progesterone and prostaglandin E2 secretion as well as angiogenic activity in the equine corpus luteum.
Cytokines and nitric oxide (NO) are potential mediators of luteal development and maintenance, angiogenesis, and blood flow. The aim of this study was to evaluate (i) the localization and protein expression of endothelial and inducible nitric oxide synthases (eNOS and iNOS) in equine corpora lutea (CL) throughout the luteal phase and (ii) the effect of a nitric oxide donor (spermine NONOate, NONOate) on the production of progesterone (P4) and prostaglandin (PG) E(2) and factor(s) that stimulate endothelial cell proliferation using equine luteal explants. Luteal tissue was classified as corpora hemorrhagica (CH; n = 5), midluteal phase CL (mid-CL; n = 5) or late luteal phase CL (late CL; n = 5). Both eNOS and iNOS were localized in large luteal cells and endothelial cells throughout the luteal phase. The expression of eNOS was the lowest in mid-CL (P < 0.05) and the highest in late CL (P < 0.05). However, no change was found for iNOS expression. Luteal explants were cultured with no hormone added or with NONOate (10(-5) M), tumor necrosis factor-α (TNFα; 10 ng/mL; positive control), or equine LH (100 ng/mL; positive control). Conditioned media by luteal tissues were assayed for P4 and PGE(2) and for their ability to stimulate proliferation of bovine aortic endothelial cells (BAEC). All treatments stimulated release of P4 in CH, but not in mid-CL. TNFα and NONOate treatments also increased PGE(2) levels and BAEC proliferation in CH (P < 0.05). However, in mid-CL, no changes were observed, regardless of the treatments used. These data suggest that NO and TNFα stimulate equine CH secretory functions and the production of angiogenic factor(s). Furthermore, in mares, NO may play a role in CL growth during early luteal development, when vascular development is more intense.
Ferreira-Dias
G
G
CIISA, Faculdade de Medicina Veterinária, TULisbon, 1300-477 Lisbon, Portugal. gmlfdias@fmv.utl.pt
Costa
A S
AS
Mateus
L
L
Korzekwa
A J
AJ
Galvão
A
A
Redmer
D A
DA
Lukasik
K
K
Szóstek
A Z
AZ
Woclawek-Potocka
I
I
Skarzynski
D J
DJ
D000818:Animals; D002417:Cattle; D002455:Cell Division; D003338:Corpus Luteum / Q000098:blood supply / Q000201:enzymology / Q000502:physiology*; D015232:Dinoprostone / Q000096:biosynthesis / Q000378:metabolism*; D042783:Endothelial Cells / Q000166:cytology / Q000201:enzymology; D005260:Female; D006736:Horses / Q000502:physiology*; D008184:Luteal Cells / Q000201:enzymology; D008183:Luteal Phase / Q000502:physiology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009569:Nitric Oxide / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D052247:Nitric Oxide Synthase Type II / Q000032:analysis; D052250:Nitric Oxide Synthase Type III / Q000032:analysis; D011374:Progesterone / Q000096:biosynthesis / Q000378:metabolism*
D020030:Nitric Oxide Donors; D009569:Nitric Oxide; D011374:Progesterone; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D015232:Dinoprostone